Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹5 Cr.
Stock P/E
25.8
P/B
0.2
Current Price
₹1.6
Book Value
₹ 10.2
Face Value
10
52W High
₹3.7
52W Low
₹ 1.4
Dividend Yield
0%

Symbiox Inv.& Tradig Overview

Business

Symbiox Investment & Trading Co Ltd. operates in the trading sector in India. Its core business involves participating in various financial markets, likely including equities, commodities, derivatives, and potentially currencies. The company's business model primarily revolves around generating profits from price differences, market fluctuations, and strategic investments. This can involve proprietary trading (trading with its own capital), arbitrage opportunities, market making, or long-term investment in securities and other assets. The company makes money through capital appreciation of its investments, realized gains from buying and selling securities, and potentially from dividends or interest income from its portfolio holdings.

Revenue Mix

Without specific financial data, the exact revenue mix or major business segments cannot be definitively stated. However, given its sector, potential segments could include:

Equity Trading/Investments: Buying and selling shares listed on stock exchanges.

Commodity Trading: Trading in various commodities like metals, energy, or agricultural products.

Derivatives Trading: Engaging in futures and options contracts for hedging or speculative purposes.

Other Investments: Potentially investing in mutual funds, bonds, or other financial instruments.

The contribution from each of these segments would depend on the company's specific strategies and market conditions.

Industry

The Indian trading industry is highly competitive and dynamic, encompassing a wide range of participants from large financial institutions, brokerage firms, mutual funds, proprietary trading desks, and individual investors. The industry is characterized by high liquidity in major asset classes but also significant price volatility. Symbiox Investment & Trading Co Ltd., as a dedicated trading entity, likely operates within this ecosystem, competing on factors such as capital base, trading strategies, risk management capabilities, and market access. Its precise positioning relative to larger financial conglomerates or more specialized trading firms would depend on its scale of operations and specific niches it might target.

MOAT

For a trading company, durable competitive advantages (moats) are generally difficult to establish and sustain. Potential factors that could act as competitive advantages, though not confirmed for Symbiox without specific information, include:

Proprietary Algorithms/Technology: Advanced trading systems that offer speed or superior analytical capabilities.

Exceptional Risk Management: A robust framework to minimize losses and protect capital.

Deep Capital Base: Sufficient capital to participate in large trades or sustain periods of market downturns.

Specialized Market Knowledge: Expertise in niche asset classes or less efficient markets.

Experienced Management/Trading Teams: A team with a proven track record of profitable trading.

Based on the limited public information, no clear and durable competitive moat can be definitively attributed to Symbiox.

Growth Drivers

Key factors that could drive growth for Symbiox over the next 3-5 years include:

Increased Market Volatility: Higher price movements in financial markets can create more trading opportunities.

Expansion of Capital Base: Increased capital allocation can allow for larger positions and diversification.

Adoption of Advanced Trading Technologies: Implementation of high-frequency trading or algorithmic strategies to improve efficiency and profitability.

Favorable Regulatory Environment: Policies that support capital market activity and innovation.

Diversification into New Asset Classes: Entering new markets or instruments to capture different opportunities.

Economic Growth: A growing Indian economy generally supports corporate earnings and investor sentiment, leading to higher market activity.

Risks

Symbiox faces several inherent risks typical of a trading and investment company:

Market Risk: Adverse price movements in the securities or commodities it trades can lead to significant losses.

Liquidity Risk: Difficulty in buying or selling certain assets quickly without affecting their price, especially in illiquid markets.

Operational Risk: Risks associated with system failures, human error, fraud, or inadequate internal processes.

Regulatory Risk: Changes in financial market regulations, taxation policies, or trading rules by SEBI or other authorities can impact operations and profitability.

Credit/Counterparty Risk: The risk that a counterparty to a transaction may fail to fulfill its obligations.

Interest Rate Risk: Changes in interest rates can affect the value of fixed-income investments or the cost of borrowed capital.

Management & Ownership

As a company in India, Symbiox Investment & Trading Co Ltd. is typically promoted and largely owned by a promoter group or founding family, which often holds a significant controlling stake. The management team would likely consist of professionals with experience in finance, investment, and risk management. Without specific disclosure, details regarding the background and quality of the current promoters, the executive management team, and the precise ownership structure (e.g., public vs. promoter shareholding percentages) are not available.

Outlook

The outlook for Symbiox Investment & Trading Co Ltd. is largely tied to the performance and volatility of the Indian financial markets, as well as its own trading acumen and risk management.

Bull Case: If the company can consistently identify profitable trading opportunities, maintain effective risk controls, and strategically deploy its capital in a growing market environment, it has the potential for significant capital appreciation and revenue growth. Favorable macroeconomic conditions and supportive capital market policies could further enhance its prospects.

Bear Case: The inherent volatility and unpredictability of financial markets pose substantial risks. Poor trading decisions, inadequate risk management, adverse market movements, or unexpected regulatory changes could lead to significant financial losses and erode its capital base. Intense competition within the trading sector also necessitates continuous innovation and efficiency.

Symbiox Inv.& Tradig Share Price

Live · BSE · Inception: 1979
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Symbiox Inv.& Tradig Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Sep 2024 Dec 2024 Mar 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Net Sales 1 0 1 1 0 1 0 0 1 0
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 1 0 1 1 0 1 0 0 1 0
Total Expenditure 1 0 1 0 0 2 0 0 1 0
Operating Profit 0 -0 -0 0 0 -0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 -0 -0 0 0 -0 0 0 0 0
Provision for Tax 0 -0 -0 0 0 -0 0 0 0 0
Profit After Tax 0 -0 -0 0 0 -0 0 0 0 0
Adjustments 0 0 -0 -0 0 0 -0 0 0 0
Profit After Adjustments 0 -0 -0 0 0 -0 0 0 0 0
Adjusted Earnings Per Share 0 -0 -0 0.1 0.1 -0.1 0 0 0 0

Symbiox Inv.& Tradig Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 1 1 2 2 1 1 2 2 4 4 3 1
Other Income 0 1 1 1 1 1 1 0 0 0 0 0
Total Income 1 2 3 3 2 2 3 2 4 4 3 1
Total Expenditure 1 2 3 3 2 2 3 2 4 4 3 1
Operating Profit 0 0 0 0 0 0 0 0 0 0 0 0
Interest 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 0 0 0 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 0 0 0 0 0 0 0 0 0 0 0
Provision for Tax 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Tax -0 0 0 0 -0 0 0 0 0 0 0 0
Adjustments 0 0 0 0 0 0 0 0 0 0 0 0
Profit After Adjustments -0 0 0 0 -0 0 0 0 0 0 0 0
Adjusted Earnings Per Share 0 0 0 0 -0 0 0 0 0.1 0.1 0.1 0

Symbiox Inv.& Tradig Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 31 31 31 31 31 31 31 31 31 32 32
Minority's Interest 0 0 0 0 0 0 0 0 0 0 0
Borrowings 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0 0
Total Current Liabilities 0 0 1 1 3 1 2 1 1 0 0
Total Liabilities 31 31 32 32 34 32 33 32 33 32 32
Fixed Assets 0 0 0 0 0 0 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0 0 0 0 0 0 0
Total Current Assets 31 31 32 32 34 32 33 32 33 32 32
Total Assets 31 31 32 32 34 32 33 32 33 32 32

Symbiox Inv.& Tradig Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0 0 0 0 0 1 0
Cash Flow from Operating Activities -1 -17 1 0 1 0 1 -0 -4 -3 4
Cash Flow from Investing Activities 1 17 -1 -0 -2 -0 -1 0 5 3 -3
Cash Flow from Financing Activities 0 0 0 0 0 0 0 0 0 0 0
Net Cash Inflow / Outflow 0 -0 0 0 -0 -0 0 0 0 -0 1
Closing Cash & Cash Equivalent 0 0 0 0 0 0 0 0 1 0 1

Symbiox Inv.& Tradig Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0 0.01 0.04 0.04 -0 0.01 0.02 0.04 0.05 0.07 0.06
CEPS(Rs) -0.03 0.01 0.04 0.04 -0 0.01 0.02 0.04 0.05 0.07 0.06
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 0 9.78 9.82 9.86 9.87 9.87 9.9 9.96 10.01 10.08 10.14
Core EBITDA Margin(%) 1.68 -218.94 -63.33 -46.27 -90.9 -89.35 -44.02 9.56 5 0.52 9.35
EBIT Margin(%) 1.68 9.12 8.08 9.61 4.1 3.06 4.52 10.25 5.42 6.37 9.4
Pre Tax Margin(%) 1.68 9.12 8.07 9.56 4.09 3.05 4.51 10.25 5.41 6.35 9.38
PAT Margin (%) -5.99 6.43 5.58 7.1 -1 2.29 3.34 7.59 4 5.34 6.94
Cash Profit Margin (%) -5.99 6.67 5.81 7.29 -1 2.29 3.34 7.59 4 5.4 7.05
ROA(%) -0.56 0.13 0.36 0.41 -0.03 0.07 0.21 0.43 0.49 0.64 0.6
ROE(%) -0.57 0.13 0.37 0.43 -0.03 0.08 0.22 0.45 0.51 0.66 0.61
ROCE(%) 0.16 0.19 0.53 0.57 0.12 0.1 0.3 0.6 0.69 0.79 0.82
Receivable days 0 0 59.13 189.81 582.46 0 0.05 86.54 76.3 38.05 11.33
Inventory Days 3.03 5.68 1.77 1.93 0 0 0 0 19.07 13.94 91.53
Payable days 0 0 43.86 143.4 467.63 386.01 208.67 466.05 108.94 80.46 30.52
PER(x) 0 2015.38 323.06 22.8 0 26.32 40.99 110.36 67.98 40.99 52.04
Price/Book(x) 0 2.68 1.18 0.1 0.06 0.02 0.09 0.49 0.35 0.27 0.31
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 21.18 130.14 18.04 1.63 2.25 0.85 1.3 8.27 2.58 2.11 3.23
EV/Core EBITDA(x) 1262.73 1390.54 217.2 16.61 54.77 27.66 28.73 80.67 47.68 32.88 33.97
Net Sales Growth(%) 0 -56.64 220.18 -8.22 -51.63 15.68 100.26 -11.96 117.6 -2.12 -29.1
EBIT Growth(%) 976.55 135.88 183.49 9.13 -79.34 -13.62 195.44 99.73 14.92 15.1 4.64
PAT Growth(%) -6288.4 146.58 177.7 16.77 -106.81 364.79 192.12 100.12 14.57 30.88 -7.86
EPS Growth(%) 0 0 176.92 16.94 -106.89 362.07 192.11 100 14.64 30.84 -7.96
Debt/Equity(x) 0 0.01 0.01 0.01 0.01 0.01 0 0 0 0 0
Current Ratio(x) 71.75 165.31 33.92 24.05 12.24 37.64 14.37 43.27 22.06 88.32 113.72
Quick Ratio(x) 71.72 165.25 33.91 24.05 12.24 37.64 14.37 43.27 21.92 88.07 109.11
Interest Cover(x) 0 1257.69 1183.29 198.6 274.78 273.46 508.72 0 1215.76 340.06 564.45
Total Debt/Mcap(x) 0 0 0.01 0.09 0.14 0.42 0 0 0 0 0

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR -25% +14% +25% +12%
Operating Profit CAGR — — — —
PAT CAGR — — — —
Share Price CAGR -39% -17% -2% -24%
ROE Average +1% +1% 0% 0%
ROCE Average +1% +1% +1% 0%

Symbiox Inv.& Tradig Shareholding Pattern

Latest · Sep 2026
100% held
Promoters 3.33 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 96.67 %
# Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Promoter 3.333.333.333.333.333.333.333.333.333.33
FII 0000000000
DII 0000000000
Public 96.6796.6796.6796.6796.6796.6796.6796.6796.6796.67
Others 0000000000
Total 100100100100100100100100100100

Symbiox Inv.& Tradig Peer Comparison

Symbiox Inv.& Tradig Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Symbiox Inv.& Tradig Pros & Cons

Pros

  • Stock is trading at 0.2 times its book value
  • Debtor days have improved from 80.46 to 30.52days.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 3.33%.
  • Company has a low return on equity of 1% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp